Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Other Accumulated Expenses (2018 - 2024)

Iovance Biotherapeutics has reported Other Accumulated Expenses over the past 5 years, most recently at $4.0 million for Q1 2024.

  • Quarterly results put Other Accumulated Expenses at $4.0 million for Q1 2024, down 7.25% from a year ago — trailing twelve months through Mar 2024 was $4.0 million (down 7.25% YoY), and the annual figure for FY2023 was $6.6 million, changed.
  • Other Accumulated Expenses for Q1 2024 was $4.0 million at Iovance Biotherapeutics, down from $6.6 million in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for IOVA hit a ceiling of $6.6 million in Q4 2023 and a floor of $4.0 million in Q1 2024.